19 Dec 2022 FINTEPLA®▼ (fenfluramine) oral solution recommended for approval in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) Member news
16 Dec 2022 Oxurion announces the continuation of KALAHARI Phase 2, Part B Study in diabetic macular edema following interim analysis Member news
09 Dec 2022 UCB announces positive Phase 3 studies for bimekizumab in hidradenitis suppurativa Member news
21 Nov 2022 Oxurion: Interim analysis for KALAHARI trial planned by year-end 2022 with full top-line data expected in second half of 2023 Member news
15 Nov 2022 Rejuvenate Biomed’s newly appointed Clinical Advisory Board endorses Clinical Phase 2b strategy in sarcopenia Member news
15 Nov 2022 Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON Member news
08 Nov 2022 New Idylla™ EGFR study shows reduction of time-to-treatment by 48% for lung cancer patients Member news
25 Oct 2022 Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON) Member news
12 Oct 2022 Mithra announces positive preclinical data demonstrating Estetrol’s efficacy in wound healing Member news
10 Oct 2022 Biocartis initiates commercialization in Europe of HepatoPredict (CE-IVD) test for liver cancer patients Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
